Claims
- 1. A method for inhibiting platelet aggregation, which comprises administering to a patient in need of such treatment a composition comprising a physiologically acceptable solid or aqueous liquid carrier and a platelet aggregation inhibiting amount of at least one active compound selected from the group consisting of:
- (a) tetrahydroxyaporphine,
- (b) glaucine containing 50 to 100% l-glaucine, and
- (c) the physiologically acceptable salts and N-alkyl ammonium salts of said compounds.
- 2. A method as defined in claim 1, wherein the active agent is selected from glaucine containing 50 to 100% l-glaucine and the physiologically acceptable salts and N-alkyl ammonium salts thereof having 1 to 4 carbon atoms in the N-alkyl group.
- 3. A method as defined in claim 1, comprising administering the composition in oral dosage unit form, each dosage unit containing between 100 and 800 mg of active agent.
- 4. A method as defined in claim 1, comprising administering the composition in form of a pill, dragee, tablet or capsule each containing between 100 and 500 mg of active agent.
- 5. A method as defined in claim 1, comprising injecting a composition containing a physiologically acceptable aqueous liquid carrier and between 10 and 200 mg of active agent per ml.
Priority Claims (1)
Number |
Date |
Country |
Kind |
2717001 |
Apr 1977 |
DEX |
|
CROSS-REFERENCE TO RELATED APPLICATION
This application is a continuation of Ser. No. 895,717 filed Apr. 12, 1978 now abandoned.
US Referenced Citations (7)
Non-Patent Literature Citations (3)
Entry |
The Pharmacological Basis of Therapeutics-pp. 279-280 (1966). |
Chem. Abst. 58 4941(h), 1963-Vernadakis et al. |
Chem. Abst. 61 9928(g), 1964-Donev. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
895717 |
Apr 1978 |
|